[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-traumatic-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-traumatic-headache":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,74,114,155,179,203,231,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100605747","symptom-exacerbation-following-mental-imagery-in-patients-with-persistent-post-concussive-symptoms-100605747",false,"NCT07166536","Symptom Exacerbation Following Mental Imagery in Patients With Persistent Post-Concussive Symptoms","Characterization of Headache and Dizziness Exacerbation Following Mental Imagery in Patients With Persistent Post-Concussive Symptoms","Inclusion Criteria:\n\n1. Current patients of Reut Rehabilitation Hospital or individuals who were discharged from the hospital within the past 12 months.\n2. Diagnosis of mild Traumatic Brain Injury, concussion, blast injury, or cervical whiplash injury.\n3. More than 3 months since the event.\n4. Presence of headaches and\u002For dizziness that began after the injury and have persisted continuously or intermittently.\n5. Exclusion of other potential causes of headaches, such as non-healed fractures, chronic inflammation\u002Finfection, increased intracranial pressure, or meningeal injury.\n6. Headache intensity of at least 3\u002F10 on the VAS scale.\n\nExclusion Criteria:\n\n1. Significant cognitive impairment preventing informed consent (Mini-Mental State Examination score \\\u003C20 or Montreal Cognitive Assessment score \\\u003C20, as per IRB requirements).\n2. Diagnosed central neurological conditions such as multiple sclerosis, Parkinson's disease, stroke, or brain tumor.\n3. Presence of known pyramidal or extrapyramidal neurological signs.\n4. Significant language impairment interfering with communication.\n5. Psychiatric disorders significantly affecting communication.\n6. Use of vestibular-suppressant medication (e.g., Cinnarizine) with an inability or unwillingness to discontinue treatment 24 hours prior to testing.\n\nWithdrawal Criteria:\n\n1\\. Oculomotor dysfunction affecting multiple oculomotor functions.","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background: Mild Traumatic Brain Injury (mTBI) often results in persistent emotional, cognitive, and somatic symptoms-such as headaches and dizziness. These symptoms impose a significant burden, yet their underlying mechanisms remain unclear.\n\nPredictive processing theories suggest that persistent symptoms may result from learned perceptual errors, particularly in individuals with high negative affectivity. This framework may help explain ongoing persistent post-concussive symptoms (PPCS) in the absence of identifiable pathology, which have been linked to various psychological factors.\n\nMental imagery (MI) is thought to engage similar predictive processes. There is evidence that MI of symptom-triggering movements may exacerbate symptoms in individuals with chronic somatic conditions. However, this phenomenon has not been studied in PPCS patients. Investigating symptom provocation through MI may yield novel insights into the neuropsychological mechanisms sustaining PPCS and potentially contribute to the development of therapeutic tools for this population.\n\nObjectives:\n\n1. Documenting the exacerbation of headache and dizziness following provocative mental imagery (imagery of movements or scenarios that elicit these symptoms in real life) in patients with PPCS.\n2. Comparing changes in headache and dizziness after provocative MI versus neutral MI (imagery of movements or scenarios that do not elicit these symptoms in real life).\n3. Comparing patients who experience symptom exacerbation following mental imagery to those who do not.\n4. Describing associations between symptom exacerbation and negative affectivity, anxiety, depression, catastrophizing, and lower daily functioning.\n\nMethods: A cross-sectional study will be conducted on adult patients experiencing PPCS following mTBI. Participants will be recruited through convenience sampling from a computerized hospital database of Reuth Rehabilitation Hospital, based on inclusion and exclusion criteria.\n\nAfter signing an informed consent form, participants will be invited to attend 2 to 3 sessions, each lasting 1 to 2 hours. During these sessions, a licensed physiotherapist will conduct a comprehensive clinical assessment, including: Completion of self-report questionnaires; A vestibular examination; Anamnestic interview and clinical assessment of individual movement- and scenario-related triggers for dizziness and headaches; Symptom provocation testing using mental imagery of the identified triggers.",[27,28,29],"Mild Traumatic Brain Injury, Concussion","Post Concussive Syndrome, Chronic","Post Traumatic Headache",[31,32,33,34],"mild traumatic brain injury","Persistent Post-Concussion Symptoms","mental imagery","concussion","RECRUITING","2026-04-09",{"date":38,"type":39},"2026-04-14","ACTUAL",{"date":41,"type":39},"2025-09-07",{"date":43,"type":21},"2026-12-31",{"name":45,"class":46},"Reuth Rehabilitation Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":47},"100521453","phase-1-greater-occipital-nerve-blockade-in-veterans-with-post-concussion-headache-sub-study-1-100521453","NCT06069791","Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1","Anesthetic Greater Occipital Nerve Blockade in Veterans With Post-Traumatic Headache: Sub-study 1","Inclusion Criteria:\n\n* United States Military Veterans within VA Connecticut Healthcare System\n* Chronic post-traumatic headache per ICHD-3 criteria (i.e., headaches are continuing to occur three months after the head injury)\n* At least two headache days per week\n* MRI brain scan completed within the past 3 months if chronic PTH for less than one year, within the past year if chronic PTH for less than 5 years, and within 5 years if chronic PTH for more than 10 years\n* Review of MRI and the medical record does not reveal another source for headache\n\nExclusion Criteria:\n\n* Skull defect\n* Other contraindication to bupivacaine\n\n  1. Allergy or adverse reaction (e.g., rash, cardiac effects) to amide anesthetics, such as lidocaine\n  2. Instruction from clinician to avoid amide anesthetics, such as lidocaine\n* Pregnant or lack of adequate birth control",{"count":56,"type":21},12,[58],"PHASE1","The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.",[61],"Post-Traumatic Headache",[63,64,65],"traumatic brain injury","veteran","VA Connecticut Healthcare System","2026-01-27",{"date":68,"type":39},"2026-01-29",{"date":70,"type":39},"2024-01-26",{"date":43,"type":21},{"name":73,"class":46},"Yale University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100471118","art-therapy-and-emotional-well-being-in-military-populations-with-posttraumatic-stress-symptoms-100471118","NCT05414708","Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms","Inclusion Criteria:\n\n* DEERS Eligible\n* Active Duty or Veteran separated within the past 10 years\n* Significant posttraumatic stress symptoms (score of \\>\u002F=31 on the PCL-5)\n\nExclusion Criteria:\n\n* History of moderate, severe, or penetrating brain injury\n* History of psychotic disorder, bipolar disorder, or active suicidal or homicidal ideation\n* History of multiple sclerosis, Huntington's disease, or Alzheimer's disease\n* History of stroke or myocardial infarction\n* History of brain tumor\n* History of seizures\n* Contradictions for MRI (for example, participants will be excluded for pregnancy, metal implants or suspected shrapnel, aneurysm\u002Fintracranial clips, cardiac pacemakers or implanted programmable devices or pumps)\n* Unable to provide informed consent\n* History of previous exposure to art therapy\n* Active substance use disorder","64 Years",{"count":82,"type":21},40,[24],"Art therapy is used across the Military Health System for treatment of posttraumatic symptoms, but there is limited research on how art therapy is able to restore emotional expression and regulation in service members. This research hopes to learn about the effects of art therapy on emotional expression and regulation in service members as well as the neurological systems at work. If a participant chooses to be in this study, he or she will attend eleven sessions over a period of six to eight months. The first session will be an interview and self-assessment questionnaires to collect information on a variety of symptoms, experiences, and personality traits, and an MRI scan. During the MRI scan, participants will be asked to perform a task where they will be shown a series of neutral and negative images. The following eight sessions will be one-hour art therapy sessions with a certified art therapist. The tenth session will consist of the same self-assessment questionnaires and another MRI scan. The final session will consist of some of the same questionnaires from the tenth visit, as well as a qualitative interview done virtually three months after the tenth visit.",[86,87,61,88,89,90,91,92,93,94,95,96,97,98,99],"PTSD","Military Activity","Posttraumatic Stress Disorder","Posttraumatic Stress Disorder, Delayed Onset","Sleep Disturbance","Nightmare","Irritable Mood","Anger","Combat and Operational Stress Reaction","Combat Stress Disorders","Military Family","Military Operations","Emotional Regulation","Emotion Processing",[86,101,102],"Military","Art Therapy","2026-01-06",{"date":105,"type":39},"2026-01-08",{"date":107,"type":39},"2022-02-01",{"date":109,"type":21},"2027-12",{"name":111,"class":112},"Walter Reed National Military Medical Center","FED",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":143,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":47},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache","65 Years",{"count":123,"type":21},21,[24],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[127,128,129,130,131,132,133,134,61,135,136,137,138,139,140,141,142],"Headache Disorders, Secondary","Brain Diseases","Headache Disorders","Nervous System Diseases","Central Nervous System Diseases","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Pain","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[144,135,141],"Post-traumatic headache","NOT_YET_RECRUITING","2026-01-05",{"date":148,"type":39},"2026-01-14",{"date":150,"type":21},"2026-02",{"date":152,"type":21},"2028-12",{"name":154,"class":46},"Danish Headache Center",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":47},"100607637","phase-3-eary-infusion-of-eptinezumab-for-treatment-of-acute-post-traumatic-headaches-elite-act-100607637","NCT07191145","Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)","EarLy Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT): a Parallel Group, Randomized, Double Blind, Placebo Controlled Trial","Inclusion Criteria:\n\n* Meet diagnostic criteria for acute post-traumatic headache as per ICHD-3 criteria\n* Meet migraine screening questionnaire criteria (MSQ score ≥ 4) during at least one of the weekly screening calls\n* Within 8 weeks after onset of PTH\n\n  \\* Imaging is not required for inclusion\n* Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.)\n\nExclusion Criteria:\n\n* Diagnosis of moderate to severe TBI\n* History of mTBI within the past 5 years\n* Pre-existing chronic migraine and its subtypes, tension-type headache, trigeminal autonomic cephalalgias, cranial neuralgias, daily headache, diagnosis of another secondary headache disorder per ICHD-3 (except medication overuse headache)\n* Concurrent use of CGRP-related treatment or botulinum toxin within the last three month for migraine\n* Substance \u002F opioids use disorder\n* Confounding chronic pain disorder \u002F clinically significant pains\n* Concurrent major injuries (long bone, rib, and spinal fractures) or surgical intervention while in hospital on initial trauma\n* On-going litigation for current trauma\n* Pregnancy\u002Fbreast-feeding\n* Uncontrolled psychiatric conditions (depression, PTSD, anxiety, functional neurological disorder)\n* Use of opioids\u002Fbarbiturates for headaches (\\> 4 days\u002Fmonth)\n* Hereditary fructose intolerance",{"count":163,"type":21},80,[165],"PHASE3","Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \\> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.",[29],[169],"Migraine","2025-12-19",{"date":172,"type":39},"2025-12-29",{"date":174,"type":21},"2026-01-01",{"date":176,"type":21},"2027-09-01",{"name":178,"class":46},"Sunnybrook Health Sciences Centre",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":47},"100610577","behavior-therapy-vs-education-for-persistent-headache-after-mild-tbi-100610577","NCT07229391","Behavior Therapy vs Education for Persistent Headache After Mild TBI","Examining a Novel Treatment for Persistent Headache After Mild Traumatic Brain Injury","Inclusion Criteria:\n\n1. Enrolled in healthcare at VA San Diego Healthcare System;\n2. History of mild TBI (mTBI), or head injury that is below the diagnostic threshold for mTBI\n3. Headache that had its lifetime onset or significantly worsened within 90 days of a concussive event\n4. Headache has persisted for at least 90 days since its onset or worsening\n5. No changes in past 3 months to medical management of headache or comorbid psychiatric symptoms, and no anticipated changes during the study interval\n6. No current participation in psychological intervention for pain or headache\n\nExclusion Criteria:\n\n1. History of moderate or severe traumatic brain injury\n2. Uncontrolled bipolar, psychotic, or substance use disorder\n3. Acute suicidality as determined by screening as \"high risk\" or has a history of suicide attempt within the past 1 year;\n4. Other factors that would preclude participation in the study",{"count":20,"type":21},[24],"This study will test a new treatment, called Headache reprocessing, for persistent post-traumatic headache. The new treatment will be compared to a headache education intervention. The main objectives of the study are to examine the feasibility, safety, and clinical appropriateness of the new treatment.",[61],[191,192,193],"Headache","Behavior therapy","Brain Injuries, Traumatic","2025-12-18",{"date":196,"type":39},"2025-12-26",{"date":198,"type":21},"2027-10-01",{"date":200,"type":21},"2030-04-01",{"name":202,"class":112},"VA Office of Research and Development",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":47},"100517277","exercise-in-postconcussion-symptoms-and-posttraumatic-headache-100517277","NCT06015451","Exercise in Postconcussion Symptoms and Posttraumatic Headache","Exercise Interventions in Patients With Postconcussion Symptoms and Posttraumatic Headache. A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age 18-65 years\n* Having sustained a minimal head injury or mild traumatic brain injury at least 2 weeks ago.\n* At least one postconcussion symptoms, of at least moderate degree, occurring within the first week after the head injury.\n* Intolerance for physical activity (self-reported and measured; including symptom exacerbation later on the test day).\n* Capable of giving informed consent.\n\nExclusion Criteria:\n\n* More than 2 years since last injury.\n* The symptoms are better explained by other conditions.\n* Severe communication problems, typically due to poor knowledge of Norwegian.\n* Severe psychiatric, neurological, somatic, or substance abuse disorders that will make it problematic to function in a group and\u002For will complicate follow-up and outcome assessment.\n* Safety concerns according to the study medical checklist.",{"count":211,"type":21},100,[24],"The goal of this clinical trial is to compare two models of delivery of guided exercise in patients with exercise intolerance after mild head injury.\n\nThe main question it aims to answer is:\n\n• Is a program that includes elements of in-house exercise and follow-up sessions, and repeated treadmill testing, superior to a program with telephone-based follow-up only?\n\nParticipants will undergo a treadmill test to determine eligibility for the study, and to determine at what intensity level their symptoms worsen (symptom threshold). Thereafter they will exercise 15-20 minutes, 3-5 times per week at 80-90% of the heart rate that was found to be the symptom threshold. One group will receive face-to-face folllow-up and repeated testing, one group will receive telephone-based follow-up only .\n\nResearchers will compare these two groups to see if closer follow-up is superior when it comes to recovery from exercise intolerance after 12 weeks of exercise.",[215,216,61,217],"Brain Concussion","Post-Concussion Syndrome","Craniocerebral Trauma",[219,220,221],"exercise intolerance","exercise","Thread mill test","2025-07-07",{"date":224,"type":39},"2025-07-08",{"date":226,"type":39},"2022-11-01",{"date":228,"type":21},"2026-09-01",{"name":230,"class":46},"St. Olavs Hospital",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":47},"100409702","acceptance-and-commitment-therapy-based-rehabilitation-of-post-concussion-symptoms-100409702","NCT04614922","Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms","Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Having sustained a minimal HI or MTBI\n* PCS\u002F PTH had evolved within 1 week after the head trauma.\n* At least one post-concussion symptoms of at least moderate degree, that affects daily life.\n* \\> 6 months post-injury.\n* First line treatment has been tried, e.g. psychoeducation, increase of physical activity and pharmacological treatments for headache\n\nExclusion Criteria:\n\n* More than 5 years since last injury.\n* Symptoms are better explained by other conditions.\n* Severe communication problems, typically due to poor knowledge of Norwegian.\n* Severe psychiatric, neurological, somatic or substance abuse disorders that will make it problematic to function in a group and\u002For will complicate follow-up and outcome assessment.",{"count":239,"type":21},48,[24],"The investigators aim to evaluate effects of an outpatient rehabilitation program based on Acceptance and Commitment Therapy compared to usual care on function in patients with post-concussion syndrome (PCS) and post-traumatic headache (PTH). This study builds on the investigators' previous observational studies and treatment studies in this patient group.",[216,61],[244],"Acceptance and Commitment Therapy",{"date":224,"type":39},{"date":247,"type":39},"2020-10-29",{"date":249,"type":21},"2026-11",{"name":230,"class":46},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":47},"100583892","spinepass-spine-self-management-techniques-for-persistent-headache-after-concussion-physical-therapy-targeting-autonomic-and-dura-mater-function-100583892","NCT06882239","SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonomic and Dura Mater Function.","SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonomic and Dura Mater Function","SPINEPASS","Inclusion Criteria:\n\n* Persistent Post-traumatic headache (PPTH) duration =or \\> 4 weeks.\n* No self-reported improvement in headache pattern in the past 3 weeks. (Patients will be asked to determine whether the usual pattern of their headaches has changed for the better over the last 3 weeks.\n* Compass-31 score \\> 21 to select patients who have evidence of ANS dysfunction which SPINEPASS aims to address.\n* Headache Impact Test (HIT6) =\\>50 to capture headache-related disability of \"some impact\" or more.\n* Headache worst intensity \\>3\u002F10 on a numerical rating scale (NRS), at least once per week.\n\nExclusion Criteria:\n\n* Contraindications for spinal or graded general exercise.\n\n  * Contraindications to spinal manual therapy at or below C5-6 level\n* Cognitive impairment\u002F language barriers affecting ability to participate.\n* Redeployment\u002Frelocation or retirement planned within the next 6 months to reduce the chances of dropouts to treatment and follow-up.\n* Rating self-confidence to manage (eliminate and or lower) headaches without abortive medication at baseline of 30% or greater.\n* Inability to attend up to 12 in-person treatment sessions for 4 months.\n* Unwilling to limit commencement of other management for PPTH during the trial period.\n* Botox for headache management within the last 8 weeks or during the trial.",{"count":260,"type":21},120,[24],"This is a prospective randomized controlled trial comparing two different physical therapy approaches to the treatment of posttraumatic headache with autonomic symptoms. AIM 1: To establish the efficacy of SPINEPASS against Standard Physical Therapy to reduce headache disability and impact amongst patients with persistent post-concussion headache. AIM 2: Demonstrate the superiority of SPINEPASS in the efficient self-management of headache. Demonstrate its appropriateness, acceptability, and feasibility and gain patient insights among patients with PPTH compared to standard PT.",[264,29],"Persistent Post-concussive Symptoms",[266,267,268,269,34,270],"Persistent post-concussion headache","autonomic","dura","physical therapy","military","2025-03-11",{"date":273,"type":39},"2025-03-18",{"date":275,"type":21},"2025-05-01",{"date":277,"type":21},"2028-09-30",{"name":279,"class":46},"The University of Queensland"]